"Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial" by Jordi Giralt

Article

Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial

Lancet Oncology (2015)

Jordi Giralt, Autonomous University of Barcelona
Jose Trigo, Hospital Virgen de la Victoria, Málaga, Spain
Sandra Nuyts, Katholieke Universiteit Leuven
Mahmut Ozsahin, University Hospital of Lausanne
Krzysztof Skladowski, Centrum Onkologii Instytut M. Sklodowskiej-Curie, Gliwice, Poland
Georges Hatoum, University of Miami
Jean-Francois Daisne, Clinique Sainte Elisabeth, Namur, Belgium
Alejandro César Yunes Ancona, Unidad de Oncología Servicios de Salud del Estado de Puebla, Puebla, Mexico
Anthony Cmelak, Vanderbilt University Medical Center
Ricard Mesía, Institut Catala d'Oncologia (ICO) – L'Hospitalet, Barcelona, Spain
Alicia Zhang, Amgen
Kelly S Oliner, Amgen
Ari VanderWalde, Amgen

Link

Disciplines

Publication Date

February 1, 2015

DOI

10.1016/S1470-2045(14)71200-8

Citation Information

Jordi Giralt, Jose Trigo, Sandra Nuyts, Mahmut Ozsahin, et al.. "Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial" Lancet Oncology Vol. 16 Iss. 2 (2015) p. 221 - 232
Available at: http://works.bepress.com/georges-hatoum/4/